Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immunocore Appoints Chairman

Published: Thursday, November 14, 2013
Last Updated: Thursday, November 14, 2013
Bookmark and Share
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.

Dr Knowles succeeds Nicholas Cross who has been Chairman since the company was founded in 2008 and will remain on the Board as Deputy Chairman.  

Dr Knowles has been a Non-Executive Director of Immunocore since 2010 and was formerly President of Group Research and a Member of the Executive Committee at F.Hoffman-LaRoche Limited, Basel, Switzerland for 12 years. Dr Knowles also served as a Board member at Genentech Inc. for over ten years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, he was Research Director, Glaxo Wellcome Europe. 

Dr Knowles has also served as Chairman of the Hever Group and the EFPIA Research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge.  

James Noble, Chief Executive Officer of Immunocore, commented: “We are extremely fortunate to have appointed someone of Jonathan’s calibre as the Executive Chairman of the Immunocore Board. His significant industry experience will support Immunocore as we continue to build our ImmTAC product pipeline and seek further partnerships with pharmaceutical companies. His willingness to commit to Immunocore is a great testament to the potential of our company.  

“We would like to take this opportunity to thank Nick Cross for his hard work and significant commitment to Immunocore as Chairman over the past five years. He supported the negotiation of the spin-out from Medigene in 2008 when Immunocore was formed and helped to secure the funding for the company since its inception. He has played an invaluable role in supporting us through our early growth phase, including with our first major commercial agreements, and we are pleased that he will continue to serve as Deputy Chairman.”  

Dr Knowles said: “I am delighted to have been appointed as the new Chairman and look forward to working more closely with my Board colleagues and the rest of the team at Immunocore to grow the company, creating novel agents that we hope will contribute significantly to curing cancer.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore Announces Re-organization of its Executive Management to Support Business Growth
Re-organization to support the continuing growth of Immunocore and Adaptimmune.
Thursday, March 27, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
IMCgp100 for has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.
Monday, November 04, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.
Thursday, October 31, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore and Genentech Enter Strategic Alliance
Licensing agreement to develop ImmTACs for multiple cancer targets.
Thursday, June 27, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Scientific News
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!